

Int'l App. No.: PCT/EP00/09442
Int'l Filing Date: 21 September 2000

✓ - 2 -

a2

12. A compound according to claim 1 for use in therapy.

13. A compound according to claim 1 for use in the treatment of depression.

14. A pharmaceutical composition which comprises a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

15. A compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of diseases or disorders where an antagonist of the 5-HT_{1B} receptor is beneficial.

16. The use of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of diseases or disorders where an antagonist of the 5-HT_{1B} receptor is beneficial.

REMARKS


This Preliminary Amendment is being made upon entry of International Application No. PCT/EP00/09442 in the §371 national phase of prosecution.

A marked version of the amended claims accompanies this paper.

An abstract on a separate sheet of paper accompanies this request.

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned at the number below. If any additional fees or charges are required by this paper the Commissioner is hereby authorized to charge Deposit account 19-2570 accordingly.

Respectfully submitted,


James M. Kanagy
Attorney for Applicant
Registration No. 29,550

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5014
Facsimile (610) 270-5090
n:\jmk\patapps\P51027\prelimamend.doc